Per the terms, Mabion is expected to produce a COVID-19 vaccine candidate antigen under the name NVX-CoV2373 beginning Dec. 2021 in compliance with the GMP standard. The commercial manufacturing agreement will run from 2022 to 2025 with an option for extension.
The commencement of the production is a result of the company's activities related to the transfer of the manufacturing process and analytical methods based on Novavax procedures and requirements, as well as preparation of the company's quality system for the implementation of a new process and product, provided for in the framework agreement with Novavax on March 3, 2021.
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Last year Mabion initiated the national and international phases of the patent application process for the use of MabionCD20 in the treatment of Multiple Sclerosis patients.
